Cargando…
Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding
BACKGROUND: Hereditary Hemorrhagic Telangiectasia (HHT) is a rare inherited disorder characterized by development of mucocutaneous telangiectases and visceral organ arteriovenous malformations, which can lead to recurrent, spontaneous bleeding and development of iron deficiency anemia. The primary o...
Autores principales: | Beckman, Joan D., Li, Quefeng, Hester, Samuel T., Leitner, Ofri, Smith, Karen L., Kasthuri, Raj S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359017/ https://www.ncbi.nlm.nih.gov/pubmed/32660636 http://dx.doi.org/10.1186/s13023-020-01453-1 |
Ejemplares similares
-
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
por: Baysal, Mehmet, et al.
Publicado: (2019) -
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
por: Faughnan, Marie E., et al.
Publicado: (2018) -
Synthetic dural graft septoplasty in epistaxis from hereditary hemorrhagic telangiectasia
por: Burckhardt B, Wilfred, et al.
Publicado: (2013) -
Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management
por: Chin, Christopher J., et al.
Publicado: (2016) -
Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia
por: Thompson, Andrew B., et al.
Publicado: (2014)